INS and early-onset autosomal dominant Alzheimer disease: Phase 2 and 3 controlled trials have been recently completed, investigating the efficacy of two IN insulin devices (ViaNase by Kurve Technology and I109 Precision Olfactory Delivery by Impel NeuroPharma) on patients with mild cognitive impairment or Alzheimer’s disease over 18 months.